CCL5 and neoplasm: Finally, the therapeutic efficacy of combining CCR5- and mPDGFRβ-directed strategies was much less than that of combining CCL5 Abs/vaccine in terms of tumor load (1.2 vs 1.07), of tumor incidence (100% vs 60%) and of peritoneal dissemination (100% vs 0%) again suggesting the superiority of CCL5 blockade + PDGFRβ vaccine over all other combinations (Figures 5 B and C).